Rationale: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies.
Acute respiratory distress syndrome (ARDS) remains a life-threatening illness characterized by dysregulated inflammation and alveolar-capillary barrier disruption (1) . Given the limited number of effective treatments for established ARDS, identification of early molecular and cellular events associated with development of ARDS can complement clinical and immunological markers of established ARDS (2, 3) and may lead to therapeutic strategies aimed at ARDS prevention (4) .
Preclinical investigation has identified pathogenic roles for vascular inflammatory responses in the development of acute lung injury. Intravascular neutrophil and platelet activation result in heterotypic neutrophil-platelet aggregate (Ne-PA) formation, with subsequent secondary capture of neutrophils, endothelial cell activation, and barrier dysfunction (5) . These events are regulated in part by lipid mediators; thromboxane A 2 (TXA 2 ) released by platelets promotes neutrophil adhesion to endothelial cells (5, 6) , whereas the specialized proresolving mediator lipoxin A 4 (LXA 4 ) and its epimer 15-epi-LXA 4 (aspirin-triggered LXA 4 [ATL]), produced during neutrophil-platelet interactions by transcellular biosynthesis (7, 8) , restrain neutrophil activation (5) . Platelet activation and aggregates have also been identified in other forms of lung disease and with hypoxemia (9, 10) . Therefore, these intravascular events may serve as biomarkers of early vascular inflammation in ARDS.
Of interest, blocking Ne-PA formation mitigates experimental ARDS (5, 6, 11) . Aspirin increases plasma levels of ATL relative to thromboxane B 2 (TXB 2 , stable metabolite of TXA 2 ) in humans (12) and is organ protective in select murine models of ARDS (5) . Thus, harnessing these biochemical mechanisms could prevent ARDS.
To test the hypothesis that circulating bioactive lipid mediators and intravascular leukocyte and platelet activation are associated with the development of ARDS, plasma levels of TXB 2 and ATL and flow cytometry parameters of circulating leukocyte and platelet activation were determined in patients at risk for ARDS who were enrolled in the LIPS-A (Lung Injury Prevention Study with Aspirin) trial (NCT01504867 [13] ). Some of the results of these studies have been previously reported in the form of an abstract (14) .
Methods Study Design and Patient Selection
The biospecimens included in this study were obtained through a preplanned ancillary study to the LIPS-A clinical trial, a multicenter, double-blind, placebocontrolled, randomized clinical trial of aspirin or placebo in patients at risk for ARDS. The full study design, study procedures, and results of the primary study are published elsewhere (13, 15) .
Sample Collection and Analysis
Peripheral blood was collected at baseline (after randomization, before administration of study drug), on study Day 1 (within 24 hours after the first dose), and on study Day 3.
Statistical Analysis
Descriptive data are summarized as mean (confidence interval [CI]), median (interquartile range [IQR] ), or n (%). To estimate the discriminatory ability of the baseline variables for the development of ARDS, standard receiver operating characteristic (ROC) analyses were conducted in subjects who: 1) had baseline data present; 2) did not develop ARDS between randomization and 12 hours after baseline draw; 3) did not receive their first dose of medication before their baseline draw; and 4) had a Lung Injury Prediction Score (LIPS) greater than or equal to 4. To compare the longitudinal profiles of the biochemical markers over time, a linear mixed model was used. Post hoc contrasts were constructed from the model to compare differences between groups at each time point. For the overall test for differences, the treatment by time interaction was used. Additional details on study design, sample preparation and measurements, and statistical analyses are provided in the online supplement.
Results

Timeline for ARDS Development
To determine the time of ARDS diagnosis relative to the time of randomization and drug administration, a timeline was established. ARDS developed in 33 of 367 (9.0%) subjects enrolled in this substudy. Of these subjects, nine developed ARDS after randomization and before the intervention, including seven patients in the aspirin group ( Figure 1A ). Of the 24 subjects who developed ARDS after the first treatment dose, 10 patients developed ARDS after initiation of aspirin treatment and 14 patients after placebo ( Figure 1B ). Despite the low number of events, there was a trend for decreased ARDS after aspirin treatment ( Figure 1B ). Demographics were similar between aspirin-and placebo-exposed groups (Table 1) included in this analysis (see online supplement for inclusion criteria). ARDS occurred in 22 patients, whereas 323 patients did not develop ARDS, with similar demographics between the two groups ( Table 2) . Plasma ATL at baseline draw was median 5.29 ng/ml (IQR, 4.2-7.11 ng/ml) in ARDS (Figure 2A ), which was significantly higher than in No-ARDS (4.03 ng/ml; IQR, 2.17-6.62 ng/ml; P = 0.04). The area under the ROC curve was 0.66 (CI, 0.57-0.75). Baseline plasma TXB 2 levels ( Figure 2B ) and the ATL/TXB 2 ratio ( Figure 2C) were not significantly different with ARDS. The area under the ROC curve was 0.50 (CI, 0.37-0.63) for TXB 2 , and 0.52 (CI, 0.38-0.66) for the ATL/TXB 2 ratio ( Figures 2B and 2C) . Together, these findings indicate that elevated baseline plasma ATL levels were associated with the development of ARDS.
Peripheral Blood Leukocyte Responses and Development of ARDS
Next, the relationship between peripheral blood leukocyte responses and the development of ARDS was determined. Baseline neutrophil counts ( Figure 3A) and Ne-PA ( Figure 3B) were not significantly different in the ARDS cohort. The area under the ROC curve was 0.66 (CI, 0.48-0.84) for neutrophil counts and 0.56 (CI, 0.34-0.77) for Ne-PA. Neutrophil CD11b surface expression measured as CD11b mean fluorescence intensity (MFI; Figure 3C ) was also not associated with ARDS development, with an area under the ROC curve of 0.71 (CI, 0.59-0.84; P = 0.06). In contrast, baseline peripheral blood total monocyte counts were significantly increased in subjects who developed ARDS (median [ Figure 3E ). Monocyte CD11b surface expression was not significantly different in the ARDS cohort, with an area under the ROC curve of 0.57 (CI, 0.36-0.78; Figure 3F ). In addition to total monocytes, subjects who developed ARDS also had significantly higher intermediate monocyte (IntMo) Figure 3H ). Together, these findings indicate that the baseline peripheral blood total monocyte counts, IntMo counts, and circulating Mo-PA were associated with the development of ARDS.
Plasma Lipid Mediator Levels and Impact of Aspirin in Patients at Risk for ARDS
To determine time-and treatment-related changes in lipid mediator levels from patients at risk for ARDS, a linear mixed model analysis on as-treated subjects was performed. Baseline mean levels of TXB 2 and ATL and the ATL/TXB 2 ratio were ORIGINAL ARTICLE similar between the aspirin and placebo groups ( Figure 4 ). In the placebo cohort, plasma TXB 2 was 0.66 ng/ml (CI, 0.55-0.8 ng/ml) at baseline, 0.63 ng/ml (CI, 0.51-0.77 ng/ml) at Day 1, and 0.88 ng/ml (CI, 0.70-0.11 ng/ml) at Day 3, which was significantly increased compared with baseline ( Figure 4A ). Baseline ATL was 4.01 ng/ml (CI, 3.52-4.57 ng/ml) and was not significantly different on Day 1 and Day 3 ( Figure 4B ). The placebo arm's baseline plasma ATL/TXB 2 ratio was 6.58 (CI, Figure 4C ), which was significantly decreased from baseline. These findings indicate a time-dependent association of TXB 2 plasma levels and the ATL/TXB 2 ratio. Aspirin significantly decreased TXB 2 relative to placebo, from 0.59 ng/ml (CI, 0.49-0.72 ng/ml) before treatment to 0.24 ng/ml (CI, 0.20-0.30 ng/ml) on Day 1 and 0.25 ng/ml (CI, 0.20-0.31 ng/ml) on Day 3 ( Figure 4A ). Plasma ATL levels did not significantly change with treatment ( Figure 4B ). As such, the ATL/TXB 2 ratio increased after aspirin treatment; the ratio increased from pretreatment level of 5.61 (CI, 4.63-6.80) to 13.1 (CI, 10.7-16.0) on Day 1 and 13.8 (CI, 11.0-17.2) on Day 3 ( Figure 4C ). These findings indicate treatmentdependent changes in plasma TXB 2 with aspirin that influenced arachidonic acid metabolism to increase the ATL/TXB 2 ratio.
Peripheral Blood Neutrophil Responses in Patients at Risk for ARDS and Impact of Aspirin
Next, time-and treatment-related changes in leukocyte responses from patients at risk for ARDS were determined. Peripheral blood mean neutrophil counts, Ne-PA, and neutrophil activation (i.e., CD11b surface expression) were quantified. In the placebo cohort, initial neutrophil counts were 9. Figure 5A ). The percent of total neutrophils that were Ne-PA was 4.53% (CI, 3.79-5.27%) at baseline, 4.35% (CI, 3.63-5.06%) on Day 1, and 4.31% (CI, 3.52-5.1%) on Day 3 ( Figure 5B ). Mean neutrophil CD11b surface expression did not significantly change from baseline to Days 1 and 3 ( Figure 5C ). Aspirin treatment did not significantly impact neutrophil counts, Ne-PA, and neutrophil CD11b expression ( Figures 5A-5C) ; however, CD11b surface expression was significantly lower with aspirin at all time points, including at baseline before aspirin exposure ( Figure 5C ). These findings indicate a time-dependent effect on peripheral blood neutrophil counts that is likely independent of aspirin administration. Next, peripheral blood total monocyte counts, Mo-PA, and mean CD11b surface expression were determined. In the placebo cohort, peripheral blood monocyte counts were not significantly different during the course of the study ( Figure 5D ). The mean percent of total monocytes that were Figure 5E ). Monocyte CD11b surface expression did not significantly change from baseline to Days 1 and 3 ( Figure 5F ). Aspirin treatment did not significantly change total monocyte counts, Mo-PA, or monocyte CD11b expression ( Figures  5D-5F ); however, like neutrophil CD11b MFI, monocyte CD11b MFI was different between treatment groups at all three time points, including at baseline before aspirin exposure ( Figure 5F ). Together, these results indicate time-dependent changes in peripheral blood Mo-PA that are likely independent of aspirin administration.
Plasma Mediator and Cellular Correlation Analysis
To uncover potential relationships between the measures of biochemical mediators and peripheral blood cells analyzed here, determinations from all available samples were used to calculate correlations (see METHODS; Figure 6 ). Plasma TXB 2 and ATL/TXB 2 were inversely related across samples (r = 20.68); however, there were no significant correlations between the lipid mediators and measures of cell counts or activation. Monocyte counts correlated positively with Mo-PA (r = 0.74), and CD11b surface expression on neutrophils correlated positively with CD11b surface expression on monocytes (r = 0.80). Of interest, Ne-PA and Mo-PA were inversely related (r = 20.60). Together, these correlations suggest that these lipid mediator levels and leukocyte numbers and activation were under distinct regulation.
Discussion
Preclinical research has increased our understanding of intravascular events underlying ARDS pathogenesis (1) . Patients are diagnosed with ARDS at the height of their illness, rendering investigation of disease pathogenesis in humans challenging. By its design, the LIPS-A trial identified patients at risk for development of ARDS, enabling investigation of early molecular and cellular pathogenesis. Results presented here demonstrate that peripheral blood total monocyte counts, Mo-PA, and plasma ATL at baseline were associated Baseline plasma aspirin-triggered lipoxin A 4 (ATL) and thromboxane B 2 (TXB 2 ) levels before the development of acute respiratory distress syndrome (ARDS). The distribution of plasma (A) ATL, (B) TXB 2 , and (C) ATL/TXB 2 at baseline in subjects who developed ARDS more than 12 hours after baseline draw versus those who never developed ARDS is shown. Insets: receiver operating characteristic curves for prediction of ARDS. Area under the curve and 95% confidence interval calculated using the Delong method and the Mann-Whitney test for differences between ARDS and no-ARDS group at baseline are provided. AUC = area under the curve; No-ARDS = did not develop ARDS. with ARDS development. The IntMo subset of total monocytes was also increased in patients who developed ARDS, and IntMo-PA were increased but did not reach statistical significance. There were timedependent and treatment (aspirin)-dependent changes in plasma levels of TXB 2 and the ratio of ATL/TXB 2 . Timedependent, but not treatment-dependent, changes were also identified in peripheral blood neutrophil counts and Mo-PA. Collectively, these findings indicate an association between select intravascular responses and ARDS development and demonstrate aspirin-dependent regulation of intravascular arachidonic acid metabolism. Timeline analysis of disease onset relative to randomization and treatment administration in the LIPS-A trial revealed that several patients developed ARDS after randomization but before study drug administration. Among these subjects, disproportionately more were assigned to receive aspirin. Exclusion of patients with established disease revealed a decreased incidence of ARDS with aspirin that nearly reached statistical significance, despite the overall low number of patients developing the disease. In view of the findings presented here, including the treatment effects on the biochemical markers, a beneficial effect for aspirin in ARDS prevention remains possible.
ORIGINAL ARTICLE
TXA 2 generation by platelets plays an important role in inflammatory responses (16) . Activated platelets can also release arachidonic acid for conversion to LXA 4 (7), which, in contrast to TXA 2 , promotes the resolution of lung inflammation and injury in experimental models (17) . Aspirin acetylation of cyclooxygenase (COX)-1 irreversibly inhibits platelet TXA 2 production, whereas aspirin-acetylated COX-2 participates in production of 15-epi-LXA 4 (i.e., ATL) (18) . Preclinical studies of lung injury indicate a pathogenic role for TXA 2 (19) and a protective role for ATL (20, 21) , suggesting that the impact of aspirin on the relative levels of these lipid mediators (i.e., ATL/TXB 2 ratio) could have accounted for differences in ARDS development with aspirin. As seen herein, TXB 2 plasma levels were decreased by aspirin. In contrast, plasma ATL levels here were already higher than ATL plasma levels reported in healthy subjects (12) and not further increased with aspirin, indicating that aspirin acetylation of COX-2 alone was not sufficient to drive further increases in plasma ATL production. Although originally coined ATL, 15-epi-LXA 4 is also produced in the absence of aspirin via arachidonic acid metabolism by cytochrome P450 enzymes and 5-lipoxygenase (22) , so ATL detection in the placebo group likely resulted from activation of this biosynthetic pathway. In healthy subjects, aspirin treatment increases ATL levels (12) , suggesting that increased oxidative stress in patients at risk for ARDS may have been a significant factor in limiting further increases in ATL production, similar to that seen in severe asthma (10) . It is notable that increased plasma ATL levels at baseline were associated with development of ARDS, consistent with engagement of counterregulatory pathways that were ultimately insufficient to prevent the development of ARDS in some patients. As such, patients at risk for ARDS demonstrate specific plasma lipid mediator responses relative to healthy subjects that can be targeted for prevention or ARDS.
The role of neutrophil activation and recruitment to the lung in development of ARDS is well established (1) . Secondary capture of neutrophils contributes in preclinical models to leukocyte recruitment in response to acute lung injury (6, 11, 21, 23) and represents a potential therapeutic target. Total neutrophil counts decreased over the course of the study, similar to time-dependent decrements in tumor necrosis factor-a, IL-1b, and IL-6 noted in LIPS-A (13). In contrast, Ne-PA did not demonstrate time-dependent changes in patients at risk for ARDS, and values remained within the expected range for healthy donors (24, 25) , which may explain why aspirin did not impact Ne-PA in these at-risk patients, in distinction to findings from experimental lung injury in animal models (21) . These results suggest a role for 
CD16
Hi , and "nonclassical" CD14 Lo
Hi subsets (26) . Acute inflammation can rapidly decrease circulating monocyte counts, with subsequent mobilization of classical monocytes from the bone marrow that mature in the circulation to intermediate monocytes and then nonclassical monocytes (27, 28) . These monocyte subsets differ in their inflammatory properties (29, 30) . Pathogenic roles for monocytes in ARDS development are apparent in experimental models of acute lung injury. Peripheral blood monocytes infiltrate inflamed lungs in a CD11/CD18-dependent manner (31) , and monocyte depletion before injury reduces measures of lung injury (32) . Conversely, monocytes recruited to injured lung can promote resolution of inflammation and a return to homeostasis (33, 34) . Mo-PA increase in patients with acute myocardial infarction and stroke, correlating with disease severity (25, 35) . Platelet-monocyte interactions, including aggregate formation, can promote intercellular signaling with inflammatory mediator generation and alteration of the inflammatory milieu (16, 36) , potentially driving the development of ARDS. Mo-PA are increased in patients diagnosed with ARDS and H1N1 (37) but had not yet been implicated in early in ARDS pathogenesis. Here, peripheral blood Mo-PA demonstrated time-dependent changes in patients at risk for ARDS and were higher than in healthy control subjects examined in Reference 25. Of note, Mo-PA were specifically associated with ARDS development. In addition, expansion of IntMo in patients who develop ARDS implies activation of unique signaling pathways related to monocyte responses. Together, these results suggest that peripheral blood total monocytes and Mo-PA could play previously unappreciated and pivotal roles early in development of ARDS and can serve as potential biomarkers for ARDS development. Future studies may enable more detailed functional analyses of Mo-PA and monocyte subsets.
Inhibition of TXA 2 without significant increase in ATL was not sufficient to regulate peripheral blood leukocyte responses in early ARDS, emphasizing that antiinflammation does not equal proresolution (38) . In view of the inability of aspirin to substantially increase ATL plasma levels, it is likely that direct administration of lipoxins or other specialized proresolving mediators would be needed to counter the strong prophlogistic factors in early ARDS and those at risk. Exogenous ATL can decrease platelet-activating factor-stimulated Ne-PA in whole blood (10) , suggesting that pharmacological increases in plasma ATL levels could provide the counterregulation for pathogenic leukocyte-platelet aggregates.
Effective medical therapies for established ARDS are lacking, emphasizing the need for early identification of at-risk patients to facilitate the development of preventive strategies (4) . The LIPS identifies patients at risk for developing ARDS (39) , and here, a LIPS of 4 or higher successfully identified at-risk patients, albeit with a lower than expected ARDS incidence rate (39 biomarkers, such as Mo-PA, to the clinical parameters may increase both the LIPS sensitivity and specificity. The biochemical circuits regulating TXA 2 and ATL generation play critical roles in the pathogenesis and resolution of acute inflammatory responses in model systems (6, 7, 11, 38) . Here, correlation analyses of the intravascular biochemical and immunological biomarkers demonstrated engagement of these pathways. Plasma ATL/TXB 2 ratio showed a strong negative correlation with plasma TXB 2 levels that was principally driven by the changes in TXB 2 , emphasizing that distinct biosynthetic pathways may be selectively regulated in platelets from subjects at risk for ARDS. In addition, neutrophil activation correlated with monocyte activation, indicating concurrent roles for both cell types on patient presentation for host responses. Ne-PA and Mo-PA were negatively correlated, consistent with differences in the regulation of these cell-cell interactions during acute lung inflammatory responses. Distinct from lipoxins' antineutrophil actions, these mediators can promote monocyte and macrophage functional responses (40) , so it was interesting to not find a significant correlation between monocyte responses and lipid mediators, suggesting an uncoupling of the immune regulation by lipoxins in the setting of early ARDS.
Here, we have uncovered intravascular responses that may contribute to early ARDS pathogenesis. A limitation of this work is that no external cohort was available to validate our findings. In addition, our 
